China Congestive Heart Failure Therapeutics Market Report 2022 to 2030

China Congestive Heart Failure Therapeutics Market Analysis

$ 3999

The China Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $0.828 Bn in 2022 to $1.455 Bn by 2030, with a CAGR of 7.3% during the forecast period of 2022-2030. The market in China is driven by a confluence of various factors including a rapidly aging population, urbanization-induced lifestyle changes that increase the incidence of cardiovascular risk factors, and ongoing efforts to develop healthcare infrastructure, all of which contribute to increased demand for therapeutics. The China Congestive Heart Failure Therapeutics Market is dominated by key players from various therapeutic segments, including AstraZeneca, Bayer, Novartis, Eli Lilly, Merck, Sanofi, Jiangsu Hengrui Medicine, Shanghai Fosun Pharmaceutical, Shenzhen Chipscreen Biosciences, Guangzhou Kangchao Pharmaceutical, among others.

ID: IN10CNPH312 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Dr. Netal Patel

Buy Now

China Congestive Heart Failure Therapeutics Market Analysis Executive Summary

The China Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $0.828 Bn in 2022 to $1.455 Bn by 2030, with a CAGR of 7.3% during the forecast period of 2022-2030.

Congestive Heart Failure (CHF) is a heart condition that develops with time. It is when the heart loses its ability to pump blood to the body. Congestive Heart Failure (CHF) management involves a multifaceted approach, encompassing lifestyle adjustments, medications, and, in certain cases, surgical interventions. Lifestyle modifications, such as dietary changes to reduce sodium intake, regular exercise within individualized limits, and weight management, play a pivotal role in mitigating symptoms and slowing disease progression. Medications commonly prescribed for CHF treatment include diuretics, ACE inhibitors, beta-blockers, and inotropic agents. Recent advancements in CHF treatment include the use of sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), which has demonstrated efficacy in improving outcomes by enhancing the heart's pumping action. Additionally, sodium-glucose cotransporter-2 (SGLT2) inhibitors, initially developed for diabetes, have shown cardiovascular benefits for CHF patients, reducing hospitalizations and mortality rates. These newer therapies represent promising avenues for improving CHF management, offering more targeted and personalized approaches to enhance patient outcomes.

CHF is more common in people over 65 in China, where the prevalence is higher at 1.39%. It affects around 1.06% of community members over 35. In China, the frequency of CHF is correlated with age, rising in frequency as people age, and gender, with men at higher risk of developing the condition. Ischemic heart disease, hypertension, and valvular heart disease are the main causes of CHF in China, with the rheumatic valvular disease being more prevalent than in other Western nations.

The market in China is driven by a confluence of various factors including a rapidly aging population, urbanization-induced lifestyle changes that increase the incidence of cardiovascular risk factors, and ongoing efforts to develop healthcare infrastructure, all of which contribute to increased demand for therapeutics.

Both global and local pharmaceutical players dominate the China Congestive Heart Failure Therapeutics Market. Strong positions are held by Jiangsu Hengrui Medicine and Shanghai Fosun Pharmaceutical among local players due to their affordable medicines and great distribution networks. Glocal companies with a significant presence due to brand names and public trust include AstraZeneca, Bayer, Novartis, etc.

Market Dynamics

Market Growth Drivers

Aging population: China's dynamic healthcare landscape greatly impacts market growth. A key factor is the demographic shift, which is characterized by a rapidly aging population. This demographic change increases the prevalence of chronic diseases, particularly heart failure, as vulnerability to cardiovascular problems increases with age. As a result, the demand for CHF treatments increases significantly.

Urbanization: China's rapid urbanization is causing revolutionary shifts in lifestyle patterns. Urban environments are characterized by a high prevalence of bad food habits, sedentary routines, and high stress levels, all of which contribute to an increased risk for cardiovascular disease. This urban lifestyle shift creates a sizable reservoir of people in need of CHF treatment.

Healthcare infrastructure development: Ongoing efforts to improve medical facilities and general healthcare accessibility help to raise awareness, diagnose CHF earlier, and provide better treatment alternatives. As the healthcare landscape evolves, the combination of an aging population, urbanization-induced lifestyle changes, and infrastructure development creates a synergistic force that is propelling market expansion in China.

Market Restraints

Affordability and accessibility: Despite advancements in healthcare infrastructure, a sector of the population continues to face barriers to accessing and affording CHF therapies. The cost of sophisticated treatments may be prohibitively expensive for some people, limiting their access to vital healthcare solutions.

Healthcare Disparities: A noticeable disparity in healthcare availability and quality exists between China's urban and rural regions. Rural communities frequently face barriers to accessing specialized CHF treatments and services due to geographic constraints and a lack of medical facilities. This healthcare discrepancy exacerbates the issues faced by rural populations, impeding the equitable growth of the CHF therapies industry.

Limited awareness and education: Inadequate awareness and education on heart failure, its risk factors, and the significance of early management pose a significant barrier. Delayed diagnosis and treatment, caused by a lack of public awareness, limit the success of CHF management plans.

Healthcare Policies and Regulatory Landscape

China's healthcare policies and regulatory bodies play an important role in defining the country's healthcare system. Guided by a goal to ensure universal access to critical healthcare services, the government has launched programs to strengthen healthcare infrastructure, increase medical service quality, and broaden insurance coverage. The National Medical Products Administration (NMPA) is the major regulatory authority in charge of drug and medical device approvals, and it plays an important role in public health by regulating the safety, efficacy, and quality of pharmaceuticals and healthcare products. The NMPA enforces high criteria for drug approval and marketing, guaranteeing adherence to international best practices. Drug regulation in China is complex and ever-changing. The NMPA is responsible for examining and approving new medications, performing inspections, and monitoring post-marketing surveillance.

Notable Recent Updates

August 2023, A traditional Chinese medicine qiliqiangxin, obtained from 11 types of herbs reduces hospitalization for heart failure and cardiovascular death in patients with heart failure and a reduced ejection fraction (HFrEF).

Competitive Landscape

Key Players:

AstraZeneca
Bayer
Novartis
Eli Lilly
Merck
Sanofi
Jiangsu Hengrui Medicine
Shanghai Fosun Pharmaceutical
Shenzhen Chipscreen Biosciences
Guangzhou Kangchao Pharmaceutical

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

China Congestive Heart Failure Therapeutics Market Segmentation

By Stage of Heart Failure

Acute Heart Failure
Chronic Heart Failure

By Drug Class

ACE Inhibitors
Beta Blockers
Angiotensin 2 Receptor Blockers
Diuretics
Aldosterone Antagonists
Others

By Route of Administration

Oral
Parenteral

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By End User

Hospitals
Speciality Clinics
Homecare
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.